ArticleEndoscopy international open2025
Optimizing endoscopic detection of precancerous gastric conditions: Single-center prospective study.
Article in Endoscopy international open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Chronic atrophic gastritis is an asymptomatic precancerous condition that can progress to extensive atrophy and/or intestinal metaplasia (IM), referred to as advanced stage of atrophic gastritis (ASAG). ASAG is a common condition with a variable prevalence worldwide reaching 45%. Narrow-band imaging (NBI) already has an established role in improving endoscopic detection of atrophy and IM. Considering the heterogeneous hospital population, this study aimed to assess the ASAG detection rate with NBI-guided biopsies compared with conventional Sydney protocol, in a European cosmopolitan city hospital. Patients and methods: This was a prospective, single-center, bi-phasic study conducted between October 2023 and March 2024, comparing ASAG detection rates using conventional Sydney protocol with optional NBI use, defined as phase 1, versus systematic NBI-guided biopsies in phase 2. Results: Of 495 eligible patients, 435 with similar demographics were included in both phases (87.8%). ASAG was detected in three patients using conventional Sydney protocol (1.43%) compared with eight patients (3.56%) using systematic NBI-guided biopsies ( Conclusions: Despite the diverse hospital population, ASAG prevalence remained low. A numerical increase in ASAG detection rate was observed with systematic NBI use compared with optional NBI use. Overall, systematic NBI-guided biopsies appear to be associated with increased rates of detection of ASAG, atrophy, and IM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.